Voie d'immunisation et séquence d'administration de l ... - TEL

tel-00827710, version 1 - 29 May 2013
Dubsky, P., Saito, H., Leogier, M., Dantin, C., Connolly, J.E., Banchereau, J., and Palucka,
A.K. (2007). IL-15-induced human DC efficiently prime melanoma-specific naive CD8+ T
cells to differentiate into CTL. Eur J Immunol 37, 1678-1690.
Dudziak, D., Kamphorst, A.O., Heidkamp, G.F., Buchholz, V.R., Trumpfheller, C.,
Yamazaki, S., Cheong, C., Liu, K., Lee, H.W., Park, C.G., et al. (2007). Differential antigen
processing by dendritic cell subsets in vivo. Science 315, 107-111.
Durand, V., Wong, S.Y., Tough, D.F., and Le Bon, A. (2004). Shaping of adaptive immune
responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol Cell Biol
82, 596-602.
Edwards, A.D., Diebold, S.S., Slack, E.M., Tomizawa, H., Hemmi, H., Kaisho, T., Akira, S.,
and Reis e Sousa, C. (2003). Toll-like receptor expression in murine DC subsets: lack of
TLR7 expression by CD8 alpha+ DC correlates with unresponsiveness to imidazoquinolines.
Eur J Immunol 33, 827-833.
Farsaci, B., Higgins, J.P., and Hodge, J.W. (2012). Consequence of dose scheduling of
sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer
130, 1948-1959.
Fayolle, C., Deriaud, E., and Leclerc, C. (1991). In vivo induction of cytotoxic T cell response
by a free synthetic peptide requires CD4+ T cell help. J Immunol 147, 4069-4073.
Fesik, S.W. (2005). Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev
Cancer 5, 876-885.
Filatenkov, A.A., Jacovetty, E.L., Fischer, U.B., Curtsinger, J.M., Mescher, M.F., and Ingulli,
E. (2005). CD4 T cell-dependent conditioning of dendritic cells to produce IL-12 results in
CD8-mediated graft rejection and avoidance of tolerance. J Immunol 174, 6909-6917.
Fontana, R., Bregni, M., Cipponi, A., Raccosta, L., Rainelli, C., Maggioni, D., Lunghi, F.,
Ciceri, F., Mukenge, S., Doglioni, C., et al. (2009). Peripheral blood lymphocytes genetically
modified to express the self/tumor antigen MAGE-A3 induce antitumor immune responses in
cancer patients. Blood 113, 1651-1660.
Fotin-Mleczek, M., Duchardt, K.M., Lorenz, C., Pfeiffer, R., Ojkic-Zrna, S., Probst, J., and
Kallen, K.J. (2011). Messenger RNA-based vaccines with dual activity induce balanced TLR-
7 dependent adaptive immune responses and provide antitumor activity. J Immunother 34, 1-
15.
Francois-Newton, V., Magno de Freitas Almeida, G., Payelle-Brogard, B., Monneron, D.,
Pichard-Garcia, L., Piehler, J., Pellegrini, S., and Uze, G. (2011). USP18-based negative
feedback control is induced by type I and type III interferons and specifically inactivates
interferon alpha response. PLoS One 6, e22200.
Frebel, H., Richter, K., and Oxenius, A. (2010). How chronic viral infections impact on
antigen-specific T-cell responses. Eur J Immunol 40, 654-663.
Freeman, G.J., Casasnovas, J.M., Umetsu, D.T., and DeKruyff, R.H. (2010). TIM genes: a
family of cell surface phosphatidylserine receptors that regulate innate and adaptive
immunity. Immunol Rev 235, 172-189.
Fuertes Marraco, S.A., Scott, C.L., Bouillet, P., Ives, A., Masina, S., Vremec, D., Jansen,
E.S., O'Reilly, L.A., Schneider, P., Fasel, N., et al. (2011). Type I interferon drives dendritic
cell apoptosis via multiple BH3-only proteins following activation by PolyIC in vivo. PLoS
One 6, e20189.
242